CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated

Camp4 Therapeutics Corp

2025-Q1 EPS reported -$0.62 revenue$858,000

Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.
Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders ongoing; safety, PK, PD data expected Q4 2025.
CTA submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes.
Nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders; GLP tox studies expected 2025.
Milestone event achieved under Fulcrum license; eligible for $0.6M payment; potential up to $70M in milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.